StrykerSYK
About: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
Employees: 53,000
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
201% more first-time investments, than exits
New positions opened: 262 | Existing positions closed: 87
18% more repeat investments, than reductions
Existing positions increased: 828 | Existing positions reduced: 704
7% more funds holding
Funds holding: 2,000 [Q3] → 2,136 (+136) [Q4]
2% more capital invested
Capital invested by funds: $106B [Q3] → $108B (+$1.8B) [Q4]
0.66% more ownership
Funds ownership: 77.14% [Q3] → 77.8% (+0.66%) [Q4]
6% less call options, than puts
Call options by funds: $518M | Put options by funds: $550M
4% less funds holding in top 10
Funds holding in top 10: 76 [Q3] → 73 (-3) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Needham Mike Matson 36% 1-year accuracy 44 / 121 met price target | 18%upside $442 | Buy Reiterated | 21 Mar 2025 |
Citigroup Joanne Wuensch 45% 1-year accuracy 18 / 40 met price target | 20%upside $450 | Buy Reinstated | 26 Feb 2025 |
Barclays Matt Miksic 48% 1-year accuracy 20 / 42 met price target | 18%upside $443 | Overweight Maintained | 10 Feb 2025 |
Financial journalist opinion
Based on 11 articles about SYK published over the past 30 days
